Semax vs Selank: Comparing the Two Russian Neuropeptides

Semax vs Selank: Comparing ACTH-Derived and Tuftsin-Derived Neuropeptides in Preclinical Research

This article is a research reference summary only. All findings are derived from peer-reviewed scientific literature, primarily from Russian academic and clinical sources alongside indexed international publications. Nothing herein constitutes medical advice or guidance for human use.

Semax and Selank represent two distinct synthetic neuropeptides developed primarily within the Russian pharmaceutical research system, each targeting different aspects of central nervous system (CNS) biology. Semax is a heptapeptide derived from the ACTH(4-7) core sequence, associated with nootropic and neuroprotective properties including BDNF upregulation. Selank is a synthetic analogue of tuftsin — the endogenous tetrapeptide Thr-Lys-Pro-Arg — with an extended stabilizing sequence and a primary research profile in anxiolytic and GABAergic modulation. Although both peptides have been used in Russian clinical and research practice for decades, their mechanisms, primary evidence bases, and pharmacokinetic profiles are sufficiently distinct to warrant separate characterization.

Semax: ACTH(4-7) Heptapeptide and BDNF Pathway Involvement

Semax carries the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to ACTH(4-7) extended by the stabilizing PGP tripeptide. It was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, under the direction of Nikolai Myasoedov and colleagues in the 1980s–90s. The ACTH(4-7) core (Met-Glu-His-Phe) is known to mediate cognitive and behavioral effects of ACTH that are independent of adrenal steroidogenesis — classical studies in the 1970s and 1980s by De Wied and colleagues (Eikelenboom & De Wied, 1977, European Journal of Pharmacology) established that ACTH fragments lacking the steroidogenic N-terminal sequence still modulate attention, memory consolidation, and avoidance behavior in rodents.

Semax's most documented molecular mechanism is upregulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB. Dolotov et al. (2006, Journal of Neurochemistry) demonstrated that intranasal Semax administration in rats significantly elevated BDNF mRNA expression in the hippocampus and frontal cortex within 1–3 hours of administration, alongside upregulation of NGF (nerve growth factor). This BDNF-elevating property is considered the primary mechanistic basis for Semax's documented effects on hippocampus-dependent learning tasks in rodent models.

Semax has also been studied in stroke and ischemia research. Gusev et al. (1997, Cerebrovascular Diseases) published one of the early clinical investigations examining Semax in ischemic stroke patients, reporting improvements in neurological recovery metrics in a placebo-controlled design. The proposed mechanism involves both BDNF-dependent neuroprotection and modulation of gene expression related to the immune/inflammatory response in peri-infarct tissue. Follow-up preclinical work by Kamensky et al. (2007, Bulletin of Experimental Biology and Medicine) expanded the ischemia-protection evidence in rat middle cerebral artery occlusion models.

Semax is registered as a pharmaceutical drug in Russia and Ukraine, available as nasal drops at defined concentrations. It is classified as a nootropic/neuroprotective agent and has been prescribed within those healthcare systems for post-stroke neurological recovery and cognitive impairment. In Western regulatory frameworks, it holds no approved status.

Selank: Tuftsin Analogue and GABAergic / Anxiolytic Mechanisms

Selank carries the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro — the native tuftsin tetrapeptide (Thr-Lys-Pro-Arg, also known as threonyl-lysyl-prolyl-arginine) extended by the Pro-Gly-Pro tripeptide stabilizer, which confers resistance to aminopeptidase degradation in nasal mucosa and plasma. Tuftsin was originally characterized by Najjar and colleagues (1970, Journal of Biological Chemistry) as a natural immunostimulatory tetrapeptide derived from the Fc region of IgG. Selank was developed as a research compound with improved stability and CNS bioavailability by the same Institute of Molecular Genetics team that developed Semax.

The primary mechanistic evidence for Selank centers on modulation of the GABAergic system. Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) demonstrated that Selank increased GABA-A receptor-mediated inhibitory tone in rodent hippocampal slices, with effects analogous to low-efficacy benzodiazepine-site modulators. Unlike classical benzodiazepines, Selank did not produce significant sedation or motor impairment at anxiolytic-equivalent doses in rodent models, suggesting a modulatory rather than agonist-level effect on GABA-A receptor function.

Selank has also been reported to influence the enkephalin/opioid system and serotonin metabolism. Naumenko et al. (2012, CNS & Neurological Disorders — Drug Targets) reviewed evidence suggesting Selank elevates levels of met-enkephalin and modulates 5-HT turnover in limbic structures, which may contribute to anxiolytic effects through opioidergic and serotonergic co-mechanisms alongside GABA.

The anxiety-related preclinical evidence base for Selank is stronger than its cognitive enhancement evidence, positioning it as a compound primarily relevant to research models of anxiety, stress response, and GABAergic pharmacology. Elevated-plus maze, light-dark box, and conditioned fear extinction paradigms have all been used to document Selank anxiolytic activity in mice and rats (Uchakina et al., 2008, Bulletin of Experimental Biology and Medicine).

Like Semax, Selank is a registered pharmaceutical in Russia, available as nasal drops, and is classified as an anxiolytic agent within that system. No regulatory approval exists in EU or US frameworks.

Pharmacokinetic Differences: Nasal Bioavailability and CNS Penetration

Both Semax and Selank are administered intranasally in published clinical and preclinical investigations. The intranasal route for CNS peptide delivery bypasses the blood-brain barrier via olfactory and trigeminal nerve fiber pathways, enabling direct CNS delivery that circumvents both peripheral enzymatic degradation and BBB exclusion (Illum, 2004, Drug Discovery Today).

Semax plasma half-life after intranasal administration is estimated at less than 30 minutes based on pharmacokinetic studies in rodents, with CNS tissue levels persisting longer due to direct olfactory uptake. The PGP extension contributes to stability relative to the parent ACTH(4-7) tetrapeptide.

Selank's Pro-Gly-Pro extension similarly extends its stability compared to native tuftsin (half-life < 10 minutes) to an estimated 15–30 minutes in plasma. Brain tissue concentrations after intranasal delivery have been measured by radiolabeled tracer studies in rats (Zozulya et al., 1999, European Neuropsychopharmacology), confirming CNS access via the nasal route.

Neither compound has published oral bioavailability data supporting gut absorption as a delivery route.

Stroke Research vs Anxiety Research: Primary Evidence Domains

The two compounds have largely distinct primary evidence bases:

Semax primary evidence: Neuroprotection, stroke/ischemia recovery, BDNF upregulation, cognitive task performance in rodents, optic nerve injury models. The ischemia research is the strongest translational strand, supported by both animal studies and a published Russian clinical trial.

Selank primary evidence: Generalized anxiety models, conditioned fear, stress-induced immunosuppression reversal, GABAergic pharmacology, enkephalin modulation. Some cognitive enhancement data exist (working memory, attention), but these are secondary to the anxiolytic evidence.

Comparison Table: Semax vs Selank

Property	Semax	Selank
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-7 + PGP)	Thr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin + PGP)
Parent peptide	ACTH(4-7) fragment	Tuftsin (IgG-derived tetrapeptide)
Primary mechanism	BDNF/TrkB upregulation; NGF elevation	GABA-A modulation; enkephalin/serotonin effects
Primary research effect	Nootropic / neuroprotective	Anxiolytic / stress-modulating
Strongest preclinical evidence	Ischemia/stroke models; cognitive tasks	Anxiety paradigms (EPM, light-dark box)
Clinical research	Ischemic stroke (Gusev et al., 1997)	Anxiety disorder studies (Russian registry)
Route of administration	Intranasal (primary); some IV studies	Intranasal (primary)
Plasma half-life (approx.)	< 30 minutes	~15–30 minutes
BBB penetration	Via olfactory/trigeminal pathways	Via olfactory/trigeminal pathways
Regulatory status	Registered drug in Russia/Ukraine	Registered drug in Russia/Ukraine
Western regulatory status	No approval (EU/US)	No approval (EU/US)
Sedation risk	Not reported at research doses	Not reported at research doses

Conclusions from the Literature

Semax and Selank are mechanistically complementary neuropeptides with distinct primary evidence domains. Semax occupies a neuroprotective/nootropic research space, supported by BDNF mechanism studies and stroke model data including one published clinical trial. Selank occupies an anxiolytic/GABAergic research space with well-characterized animal model evidence and a distinct receptor pharmacology from classical benzodiazepines.

The primary limitation of both compounds from a Western research perspective is the heavy concentration of studies in Russian-language journals, some of which are not indexed in major English-language databases. Researchers should access translated or bilingual versions of primary sources where available. The Dolotov et al. (2006) and Semenova et al. (2010) publications represent the most accessible English-language mechanistic characterizations for Semax and Selank respectively.

Both compounds are research-only agents outside Russia and are not approved by FDA, EMA, or equivalent bodies.